CLE-100
- Generic Name
- CLE-100
A Study of CLE-100 (oral Esketamine) As an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
Phase 2
Recruiting
- Conditions
- Adjunctive Treatment of Major Depressive Disorder (MDD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Clexio Biosciences Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06340958
- Locations
- 🇺🇸
Clinical Site 139, La Jolla, California, United States
🇺🇸Clinical Site 131, Lafayette, California, United States
🇺🇸Clinical Site 130, Upland, California, United States
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
Phase 2
Completed
- Conditions
- Adjunctive Treatment of Major Depressive Disorder
- Interventions
- Drug: placebo
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Clexio Biosciences Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT04103892
- Locations
- 🇺🇸
Clinical Site 112, Torrance, California, United States
🇺🇸Clinical Site 110, Las Vegas, Nevada, United States
🇺🇸Clinical Site 131, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath